All data are based on the daily closing price as of August 1, 2025
h

Handa Pharmaceuticals

6620.TWO
2.75 USD
0.01
+0.36%

Overview

Last close
2.75 usd
Market cap
388.61M usd
52 week high
6.00 usd
52 week low
1.57 usd
Target price
6.68 usd

Valuation

P/E
24.6269
Forward P/E
N/A
Price/Sales
15.5786
Price/Book Value
4.1311
Enterprise Value
370.15M usd
EV/Revenue
13.3458
EV/EBITDA
22.6202

Key financials

Revenue TTM
27.74M usd
Gross Profit TTM
27.70M usd
EBITDA TTM
14.06M usd
Earnings per Share
0.11 usd
Dividend
0.05 usd
Total assets
N/A usd
Net debt
N/A usd

About

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
  • Symbol
    6620.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Guo-Chun Song Ph.D.
  • Headquarter
    Tainan City
  • Web site
    https://www.handapharma.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top